UNSPSC 51314369: Pheniramine/phenylpropanolamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314369 Pheniramine/phenylpropanolamine/pyrilamine is a Commodity code that maps poorly to recent state and local procurement activity. The three opportunities posted since January 2026 involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through authorized wholesalers—none of which fall under the antihistamine/decongestant combination scope the code nominally describes. The mismatch suggests the code sees limited relevant activity in current state and local solicitations, or that issuing bodies are tagging pharmaceutical purchases with codes that do not align with their actual contents.

The one opportunity that touches on pharmaceuticals broadly is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026), which represents a multi-state cooperative vehicle with participating jurisdictions across Minnesota and Oregon and requiring manufacturers to work through three authorized wholesalers with specific pricing and EDI compliance. Seminole County, Florida issued a competitive bid for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023), and the Texas Health and Human Services Commission posted an exploratory RFI on direct-to-manufacturer prescriptions (HHS0017013, due April 3, 2026). Neither directly addresses the antihistamine compounds the code nominally covers. Without evidence of active state or local solicitation specifically for pheniramine or phenylpropanolamine products, the code does not currently signal demand for business development focus.